NO20090578L - Farmasoytisk sammensetning inneholdende en tetrahydrofolsyre - Google Patents

Farmasoytisk sammensetning inneholdende en tetrahydrofolsyre

Info

Publication number
NO20090578L
NO20090578L NO20090578A NO20090578A NO20090578L NO 20090578 L NO20090578 L NO 20090578L NO 20090578 A NO20090578 A NO 20090578A NO 20090578 A NO20090578 A NO 20090578A NO 20090578 L NO20090578 L NO 20090578L
Authority
NO
Norway
Prior art keywords
tetrahydrofolic acid
pharmaceutical composition
composition containing
estrogen
progestogen
Prior art date
Application number
NO20090578A
Other languages
English (en)
Other versions
NO20090578A (no
NO347567B1 (no
Inventor
Kristina King
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36763829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090578(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of NO20090578L publication Critical patent/NO20090578L/no
Publication of NO20090578A publication Critical patent/NO20090578A/no
Publication of NO347567B1 publication Critical patent/NO347567B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Foreliggende oppfinnelse vedrører faste farmasøytiske sammensetninger, især orale prevensjonsmidler, omfattende et progestogen, slik som drospirenon; et østrogen, slik som etinyløstradiol; en tetrahydrofolsyre eller et farmasøytisk akseptabelt salt derav, slik som kalsium-5-metyl-(6S)-tetrahydrofolat og minst en farmasøytisk akseptabel eksipiens eller bærer. Sammensetningene ifølge oppfinnelsen gir god stabilitet av tetrahydrofolsyren ved lagring mens de fortsatt sikres en rask og pålitelig frigivelse av østrogenet og progestogenet til stede i sammensetningen.
NO20090578A 2006-07-06 2007-06-29 Farmasøytisk sammensetning inneholdende en tetrahydrofolsyre NO347567B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06014002 2006-07-06
PCT/EP2007/005764 WO2008003432A1 (en) 2006-07-06 2007-06-29 Pharmaceutical composition containing a tetrahydrofolic acid

Publications (3)

Publication Number Publication Date
NO20090578L true NO20090578L (no) 2009-03-09
NO20090578A NO20090578A (no) 2009-03-09
NO347567B1 NO347567B1 (no) 2024-01-15

Family

ID=36763829

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090578A NO347567B1 (no) 2006-07-06 2007-06-29 Farmasøytisk sammensetning inneholdende en tetrahydrofolsyre

Country Status (31)

Country Link
EP (2) EP2040683B2 (no)
JP (1) JP2009542591A (no)
KR (2) KR20090033889A (no)
CN (3) CN101489563A (no)
AR (2) AR061958A1 (no)
AU (1) AU2007271449B2 (no)
BR (1) BRPI0713565B8 (no)
CA (2) CA2656131C (no)
CL (1) CL2007001962A1 (no)
CO (1) CO6150125A2 (no)
CR (1) CR10549A (no)
CU (1) CU20090004A7 (no)
EC (1) ECSP099030A (no)
ES (1) ES2626838T5 (no)
GT (1) GT200900001A (no)
IL (3) IL196027A0 (no)
MA (1) MA30598B1 (no)
MX (1) MX2009000079A (no)
MY (1) MY169516A (no)
NO (1) NO347567B1 (no)
NZ (1) NZ573766A (no)
PE (3) PE20120375A1 (no)
PH (1) PH12012501774B1 (no)
RU (2) RU2479306C2 (no)
SG (1) SG188869A1 (no)
TN (1) TNSN08543A1 (no)
TW (2) TW201538161A (no)
UA (2) UA100228C2 (no)
UY (1) UY30462A1 (no)
WO (1) WO2008003432A1 (no)
ZA (4) ZA200900868B (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
UY32836A (es) * 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
KR20130097073A (ko) * 2010-04-15 2013-09-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 초저-용량의 ｈｒｔ용 고체 경구 투여 형태
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
CN102516247A (zh) * 2010-12-15 2012-06-27 连云港金康医药科技有限公司 A型l-5-甲基四氢叶酸钙盐多晶型及其制备方法
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP2781214A1 (en) * 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
EP2878600B1 (en) 2013-12-02 2018-06-27 Cerbios-Pharma S.A. Stable complexes of an alkaline earth metal salt of N5-methyl-tetrahydrofolic acid and a polyol
CN107812195B (zh) * 2014-09-04 2021-04-20 连云港金康和信药业有限公司 (6s)‐5‐甲基‐四氢叶酸钙盐的稳定药物组合物
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
MA44206B1 (fr) 2015-06-18 2021-04-30 Estetra Sprl Comprimé orodispersible comprenant estetrol
EP3701944B1 (en) 2015-06-18 2021-12-08 Estetra SRL Orodispersible dosage unit containing an estetrol component
CU24523B1 (es) 2015-06-18 2021-06-08 Estetra Sprl Unidad de dosificación orodispersable que contiene un componente estetrol
CN105030779A (zh) * 2015-07-21 2015-11-11 福格森（武汉）生物科技股份有限公司 一种(6s)-5-甲基四氢叶酸钙口服营养补充剂及其制备方法
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CN106336444A (zh) * 2016-08-23 2017-01-18 国家卫生计生委科学技术研究所 一种新晶型炔雌醇
CN107446458A (zh) * 2017-08-04 2017-12-08 合众（佛山）化工有限公司 一种高耐水性的丙烯酸改性聚氨酯杂化树脂水性涂料
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
EP3781171B1 (en) 2018-04-19 2022-02-09 Estetra SRL Compounds and their uses for alleviating menopause-associated symptoms
CN110237046B (zh) * 2019-03-29 2021-07-30 福格森（武汉）生物科技股份有限公司 一种l-5-甲基四氢叶酸微囊的制备方法
CN110548034A (zh) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 一种怀孕阻断药物
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
IT202100008834A1 (it) * 2021-04-08 2022-10-08 Ind Chimica Srl Processo per la preparazione di drospirenone come polvere fine tramite duplice cambio di forma cristallina
CN114569567B (zh) * 2021-12-20 2023-03-14 南通联亚药业股份有限公司 一种稳定的双醋炔诺酮炔雌醇复方片及其制备方法
CN115813937B (zh) * 2022-12-01 2025-04-11 南通联亚药业股份有限公司 一种稳定的包含屈螺酮和雌二醇的药物组合物及其制备方法
CN116036033A (zh) * 2023-01-06 2023-05-02 青岛润昕德生物医药有限公司 一种地屈孕酮片及其生产工艺
IT202300027360A1 (it) * 2023-12-20 2025-06-20 Lesaffre & Cie Formulazioni solide di folati
CN117771389A (zh) * 2023-12-28 2024-03-29 浙江圣达生物药业股份有限公司 L-5-甲基四氢叶酸钙-γ-环糊精包合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347125A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
FR2676927B1 (fr) * 1991-05-29 1995-06-23 Ibf Microspheres utilisables pour les occlusions vasculaires therapeutiques et solutions injectables les contenant.
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
DE4426709A1 (de) 1994-07-20 1996-01-25 Schering Ag Steroidale Sexualhormone enthaltende feste Arzneiformen
EP0782449B1 (en) * 1994-09-22 2003-04-09 Akzo Nobel N.V. Process of making dosage units by wet granulation
RU2073529C1 (ru) * 1995-05-16 1997-02-20 Центральный научно-исследовательский рентгенорадиологический институт Композиция для эмболизации кровеносных сосудов
CH693255A5 (de) 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
CA2329005C (en) 1998-04-17 2006-01-03 Ortho-Mcneil Pharmaceutical, Inc. Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
DK1380301T3 (da) * 1999-08-31 2009-04-20 Bayer Schering Pharma Ag Farmaceutisk sammensætning af ethinylestradiol og drospirenon til anvendelse som svangerskabsforebyggende middel
RU2269342C2 (ru) * 1999-08-31 2006-02-10 Шеринг Акциенгезелльшафт Фармацевтическая комбинация этинилэстрадиола и дроспиренона для использования в качестве контрацептива
AU2001225413B2 (en) * 2000-01-18 2005-06-23 Bayer Schering Pharma Aktiengesellschaft Drospirenone for hormone replacement therapy
US6550482B1 (en) * 2000-04-21 2003-04-22 Vascular Control Systems, Inc. Methods for non-permanent occlusion of a uterine artery
US6864774B2 (en) 2000-10-19 2005-03-08 Matsushita Electric Industrial Co., Ltd. Inductance component and method of manufacturing the same
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
EP1216712A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
US6537569B2 (en) * 2001-02-14 2003-03-25 Microvention, Inc. Radiation cross-linked hydrogels
JP5037779B2 (ja) * 2002-02-21 2012-10-03 バイエル ファーマ アクチエンゲゼルシャフト １又は複数のステロイド、１又は複数のテトラヒドロ葉酸成分およびビタミンｂ１２を含む医薬組成物
WO2004039425A1 (ja) * 2002-10-29 2004-05-13 Toray Industries, Inc. 血管塞栓材料
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
MX2009000256A (es) * 2006-07-06 2009-02-18 Bayer Schering Pharma Ag Preparaciones farmaceuticas para la anticoncepcion y para prevenir el riesgo de malformaciones congenitas.
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
RU61120U1 (ru) * 2006-10-13 2007-02-27 Закрытое акционерное общество "ААА-КОМПАНИ" Средство для эмболизации сосудов
RU62008U1 (ru) * 2006-10-13 2007-03-27 Закрытое акционерное общество "ААА-КОМПАНИ" Средство для эмболизации сосудов
US8916188B2 (en) * 2008-04-18 2014-12-23 Abbott Cardiovascular Systems Inc. Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block

Also Published As

Publication number Publication date
BRPI0713565B8 (pt) 2021-05-25
AU2007271449A1 (en) 2008-01-10
UA105078C2 (uk) 2014-04-10
MX2009000079A (es) 2009-01-23
PH12012501774A1 (en) 2015-09-21
CU20090004A7 (es) 2011-07-11
CR10549A (es) 2009-01-27
HK1131917A1 (en) 2010-02-12
EP2040683B2 (en) 2023-08-16
CN101484143B (zh) 2012-07-04
IL245355B (en) 2019-05-30
CU23902B1 (no) 2013-06-28
CA2856344A1 (en) 2008-01-10
SG188869A1 (en) 2013-04-30
ES2626838T3 (es) 2017-07-26
ES2626838T5 (es) 2024-03-14
RU2624236C2 (ru) 2017-07-03
TW200812593A (en) 2008-03-16
AR061958A1 (es) 2008-08-10
KR20130042638A (ko) 2013-04-26
CN101484143A (zh) 2009-07-15
ZA201808084B (en) 2021-06-30
CN102813663B (zh) 2019-03-22
IL245355A0 (en) 2016-06-30
UY30462A1 (es) 2008-02-29
WO2008003432A1 (en) 2008-01-10
PE20120375A1 (es) 2012-05-23
CA2656131C (en) 2015-10-13
BRPI0713565A2 (pt) 2012-03-20
CA2856344C (en) 2017-02-28
PH12012501774B1 (en) 2015-09-21
CA2656131A1 (en) 2008-01-10
CO6150125A2 (es) 2010-04-20
GT200900001A (es) 2009-12-08
PE20150287A1 (es) 2015-03-15
NO20090578A (no) 2009-03-09
MY169516A (en) 2019-04-22
CN101489563A (zh) 2009-07-22
UA100228C2 (uk) 2012-12-10
EP2040683B1 (en) 2017-03-01
EP2040683A1 (en) 2009-04-01
CL2007001962A1 (es) 2008-01-04
AR106561A2 (es) 2018-01-24
NZ573766A (en) 2011-05-27
TWI508730B (zh) 2015-11-21
AU2007271449B2 (en) 2013-07-11
RU2009103649A (ru) 2010-08-20
IL224484A (en) 2016-05-31
BRPI0713565B1 (pt) 2021-02-02
TW201538161A (zh) 2015-10-16
JP2009542591A (ja) 2009-12-03
TNSN08543A1 (en) 2010-04-14
RU2012133154A (ru) 2014-02-10
EP2422774A1 (en) 2012-02-29
PE20080273A1 (es) 2008-05-16
EP2422774B1 (en) 2015-08-12
NO347567B1 (no) 2024-01-15
ZA201808083B (en) 2021-06-30
ECSP099030A (es) 2009-02-27
ZA200900868B (en) 2021-05-26
CN102813663A (zh) 2012-12-12
MA30598B1 (fr) 2009-07-01
ZA201501673B (en) 2016-02-24
KR20090033889A (ko) 2009-04-06
RU2479306C2 (ru) 2013-04-20
IL196027A0 (en) 2009-09-01

Similar Documents

Publication Publication Date Title
MY169516A (en) Pharmaceutical composition containing a tetrahydrofolic acid
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
WO2007048219A3 (en) Sustained drug release composition
CL2009002187A1 (es) Composicion farmaceutica anticonceptiva que comprende 5-metil-(6s)-tetrahidrofolato, estrogenos y/o progestagenos, opcionalmente vitamina b6 y/o vitamina b2 y coadyuvantes/vehiculos; kit; proceso para prepararla; uso para reducir el riesgo de enfermedades y malformaciones congenitas por carencia de folato (div. sol. 1130-06).
TW200716137A (en) Tanaproget compositions containing ethinyl estradiol
BRPI0514196A (pt) composição, uso de composto, kit farmacêutico, e, método de contracepção de um mamìfero
CL2010000816A1 (es) Formulacion adecuada para administracion subcutanea que comprende al menos 100 mg/ml de ctlaig, un azucar, y un portador acuoso farmaceuticamente estable; articulo de fabricacion que comprende al menos un recipiente que contiene la formulacion antes mencionada. (divisional solicitud n° 3597-06)
TW200837074A (en) Extended triterpene derivatives
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
MX2010003923A (es) Formulacion farmaceutica de valsartan.
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
AR061959A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
ECSP055629A (es) COMPOSICIÓN QUE CONTIENE UN ESTEROIDE 11ß-HALOGENADO ANDRÓGENO Y UN GESTÁGENO ASÍ COMO UN CONTRACEPTIVO MASCULINO SOBRE LA BASE DE ESTAS COMPOSICIONES
NO20045385L (no) Farmasoytisk preparat inneholdende okskarbazepin med kontrollert frigivelse av aktivt stoff
PT1526856E (pt) Composição farmacêutica que compreende derivados do estretol para ser utilizada no tratamento do cancro
PE20070188A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
GB0202635D0 (en) Formulation containing novel anti-inflammatory androstane derivative
WO2008070354A3 (en) 5- and 6- substituted benzimidazole thiophene compounds
NO20065898L (no) 1-heterocyklyl-1,5-dihydro-pyrido[3,2-b]indol-2-oner
WO2007031326A3 (de) Retardformulierung von 3-(2-dimethylaminomethyl-cyclohexyl)-phenol
UA94275C2 (ru) Фармацевтическая композиция, которая содержит по крайней мере один активный наркотический или психотропный компонент, назначенный способ введения которых в организм тяжело поддается изменению
GEP20135819B (en) 3-(2,2,2-trimethylhydrazinium) propionate dihydrate composition of local administration
AU2001292423A1 (en) Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid
WO2007052167A3 (en) Stable composition for a pharmaceutical formulation containing olanzapine

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE